Pharmacological Evaluation of Trichosanthese Dioica for Management of Alzheimer and Other Dementia Disorders
DOI:
https://doi.org/10.63682/jns.v14i18S.5258Keywords:
Cucurbitacin, Donepezil, cell viability,reduced oxidative stressAbstract
Investigate the compound’s ability to inhibit acetylcholinesterase, which could contribute to memory enhancement by performing the in-vitro and in-vivo activity. By achieving these objectives, the research will contribute to identifying new, natural therapeutic options for memory enhancement and the treatment of cognitive decline. Additionally, it may pave the way for further studies on the use of Trichosanthese dioica and other herbal compounds in brain health. Pharmacological evaluation of cucurbitacins (B and E) extracted from T.dioica for Antialzhiemer’s approach 3 core Invivo and invitro evaluation study were done for neuroprotective, antioxidant, and acetylcholinesterase inhibition. Both Cucurbitacin B and E exhibited multi-targeted protective effects against Alzheimer’s disease in vitro. They improved cell viability (MTT assay), reduced oxidative stress (DCFDA), decreased inflammatory cytokines (ELISA), and inhibited AChE (Elman’s method). Among the two, Cucurbitacin E consistently showed superior performance, highlighting its promise as a neuroprotective agent for Alzheimer’s therapy.The combination treatments (Donepezil + Cucurbitacin B or E) showed the most effective reduction in ROS, indicating that these compounds might work together to attenuate oxidative stress. The combination groups (CB+Donepezil and CE+ Donepezil) showed slightly lower TNF-α and IL-6 levels than Donepezil alone, Donepezil (78.6%) and Cucurbitacin E (76.4%) significantly restored alternation behavior. Cucurbitacin B (65.8%) also improved performance, though to a lesser extent. Cucurbitacin E emerges as a more potent neuroprotective agent than Cucurbitacin B, offering a strong rationale for its further development as a natural therapeutic lead in Alzheimer’s disease management. This study not only validates the ethno pharmacological use of Trichosanthese dioica but also provides a scientific foundation for the pharmacological advancement of Cucurbitacin based compounds.
Downloads
Metrics
References
P Tiwari, B Kumar, M Kaur, G Kaur, and H Kaur. Phytochemical screening and extraction: A review. Int. J. Pharm. Pharm. Sci,1(1):98–106, 2011
R Gupta, A Sharma, and N Kumar. Neuroprotective effects of flavonoids in Trichosanthese dioica: A potential alternative for Alzheimer’s therapy. J. Tradit. Complement. Med.12(3):122–130, 2022.
S Ghosh and S Das. Phytochemical and medicinal properties of Trichosanthese dioica Roxb.: A review. IJPSR 8(5):2165–2175, 2017.
P Singh, S Sharma, and S Verma. Role of saponins in neurodegenerative disorders: A study on Trichosanthese dioica."J. Ethnopharmacol, 250:112387–112387, 2020.
R Singh, S Sharma, and A Kumar. Neuroprotective role of saponins from medicinal plants. J. Med. Plant Res., 14(3):47–54, 2020.
H Y Zhang, X C Tang, and A Huperzine. A promising drug for Alzheimer’s disease. ActaPharmacol Sin,29(8):871–878, 2008.
A Kumar, R Singh, and V Yadav. Antioxidant and hepatoprotective properties of Trichosanthese dioica: Potential role in cognitive disorders. Asian Pac. J. Trop. Biomed.11(2):75–82, 2021.
C C Tan, J T Yu, and H F Wang. Efficacy of donepezil, rivastigmine, and galantamine for Alzheimer’s disease: a meta-analysis. J Alzheimer’s Dis, 41(2):615–631,
D Wilkinson, J Murray, C Ballard, and E Perry. Cholinesterase inhibitors used in the treatment of Alzheimer’s disease: The relationship between pharmacological effects and clinical efficacy. Drugs & Aging, 21(7):453–478, 2004.
M S García-Ayllón, D H Small, J Avila, and J Sáez-Valero. Revisiting the role of acetylcholinesterase in Alzheimer’s disease: Cross-talk with P-tau and β-amyloid. Front. Mol. Neurosci,4:22–22, 2011.
UfukOkkay , Irmak FerahOkkay In vitro neuroprotective effects of allicin on Alzheimer’s disease model of neuroblastoma cell line, J Surg Med. 2022;6(2):209-212
GuluzarOzbolat, Ares Alizade,In vitro studies on the protective effect of Tannic acid of U87 cells induced by beta- amyloid, J Basic Clin Health Sci 2021; 3: 213- 217
L M Maboko , A Theron , J-L Panayides , W Cordier , D Fisher , V Steenkamp, Evaluating Blood-Brain Barrier Permeability, Cytotoxicity, and Activity of Potential Acetylcholinesterase Inhibitors: In Vitro and In Silico Study, Pharmacol Res Perspect, 2024 Dec;12(6):e70043, doi: 10.1002/prp2.70043.
F Ali, M I Khan, and A Ahmad. Amyloid beta-protein and Alzheimer’s disease: the mechanism of toxicity and therapeutics. J MolNeurosci, 45(1):115–126, 2011.
H Hampel, M. M Mesulam, and A C Cuello. Revisiting the cholinergic hypothesis in Alzheimer’s disease. Front. Aging Neurosci.10:422–422, 2018.
J Hardy and G A Higgins. Alzheimer’s disease: The amyloid cascade hypothesis. Science, 256(5054):184–185, 1992.
O Weinreb, S Mandel, T Amit, and M B H Youdim. Neurological implications of green tea polyphenols in Alzheimer’s and Parkinson’s diseases. J. Nutr. Biochem.15(9):506–516, 2004.
H Hampel, M. M Mesulam, A C Cuello, A S Khachaturian, A Vergallo, M R Farlow, P J Snyder, E Giacobini, and Z S Khachaturian. Revisiting the cholinergic hypothesis in Alzheimer’s disease: Emerging evidence from translational and clinical research. J.Prev of Alzh’s Dis, 5(1):2–7, 2018.
K Bartus. On neurodegenerative diseases, models, and treatment strategies. Proc. of the National Acad. of Scie, 97(23):12577–12584, 2000
A Kumar, R Singh, and V Yadav. Antioxidant and hepatoprotective properties of Trichosanthese dioica: Potential role in cognitive disorders. Asian Pac. J. Trop. Biomed11(2):75–82, 2021.
J Hardy and G A Higgins. Alzheimer’s disease: The amyloid cascade hypothesis. Science, 256(5054):184–185, 1992.
Feldman HH, Lane R. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer’s disease. J. Neur, Neurosurgery & Psychiatry. 2007 Oct 1;78(10):1056-63.
Piura Y, Tipton P, Satyadev N, Graff-Radford N, Day G. Performance of Autoimmune Encephalitis Diagnostic Criteria in Patients with Suspected Rapidly Progressive Dementia Due to Autoimmune Encephalitis (P9-8.008). Neurology 2025 Apr 8; 104:5043
Hitzeman N. Cholinesterase inhibitors for Alzheimer’s disease. Am Fam Physician.2006 Sep 1;74(5):747-9.
Feldman HH, Lane R. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer’s disease. JNNP, 2007 Oct 1;78(10):1056-63.
Hitzeman N. Cholinesterase inhibitors for Alzheimer’s disease. American Family Physician. 2006 Sep 1;74(5):747-9.
Shankar GM, Walsh DM. Alzheimer's disease: synaptic dysfunction and Aβ. Mol. Neurodegener,2009 Dec; 4:1-3.
García-Ayllón MS, Small DH, Avila J, Sáez-Valero J. Revisiting the role of acetylcholinesterase in Alzheimer’s disease: cross-talk with P-tau and β-amyloid. Front. Mol. Neurosci. 2011 Sep 13; 4:22.
Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A. Donepezil and memantine for moderate-to-severe Alzheimer's disease. NEJM, 2012 Mar 8;366(10):893-903.
Fanali C, Haddad PR, Poole CF, Riekkola ML. Liquid chromatography: Fundamentals and instrumentation. InLiquid Chromatography: Fundamentals and Instrumentation: Second Edition 2017 (Vol. 1, pp. 1-784). Elsevier.
Nahar L, Sarker SD. Chemistry for pharmacy students: general, organic and natural product chemistry. John Wiley & Sons; 2019 Aug 26.
H Ferreira-Vieira T, M Guimaraes I, R Silva F, M Ribeiro F. Alzheimer's disease: targeting the cholinergic system. Curr. Neuropharmacol. 2016 Jan 1;14(1):101-15.
J Cummings, G Lee, P Nahed, M Kambar, K Zhong, J Fonseca, and K Taghva. Alzheimer’s disease drug development pipeline: 2019. TRCI, 2019, 5:272–293.
Pedersen DS, Rosenbohm C. Dry column vacuum chromatography. Synthesis. 2001;2001(16):2431-4.
A Pandey, R Tripathi, K KMaurya, and A K Tiwari. Screening of phytochemicals for acetylcholinesterase inhibition using molecular docking approach. Indian J Pharm Sci, 2020, 82(6):961–967.
Anand P, Singh B. A review on cholinesterase inhibitors for Alzheimer’s disease, Arch Pharm Res.2013 Apr; 36:375-99.
Kim GH, Kim JE, Rhie SJ, Yoon S. The role of oxidative stress in neurodegenerative diseases. Exp. Neurobiol. 2015 Oct 12;24(4):325.
C C Tan, J T Yu, and H F Wang. Efficacy and safety of donepezil, rivastigmine, and galantamine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis, 41(2):615–646, 2014.
S Gupta and R Mukhopadhyay. Advances in column chromatography: Applications in natural product isolation. J. Chromatogr. Sci, 57(6):485–496, 2019.
M A Lovell, J D Robertson, W J Teesdale, J L Campbell, and W R Markes-bery. Copper, iron, and zinc in Alzheimer’s disease senile plaques. J NeurolSci, 158(1):47–52, 1998.
J Massoulié. The Origin of Cholinesterases and the Roles of Alternative Splicing in Producing Multiple Molecular Forms. Chem. -Biol. Interact.187(1-3):88–93, 2002.
Harborne JB. Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis. 3rd ed. London: Springer; 1998.
R Howard, R Mcshane, and J Lindesay. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med, 366(10):893–903, 2012.
R T Bartus. On neurodegenerative diseases, models, and treatment strategies. Proceedings of the Proc. Natl. Acad. Sci. U.S.A.., 97(23):12577–12584, 2000.
A Kumar, A Singh, and Ekavali. A review on Alzheimer’s disease pathophysiology and its management: Pharmacol. Rep., 68(5):956–965, 2016.
P I Moreira, C Carvalho, X Zhu, M A Smith, and G Perry. Mitochondrial dysfunction is a trigger of Alzheimer’s disease pathophysiology. BiochimBiophysActa, 1802(1):2–10, 2010.
J S Birks and R J Harvey. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev., 6:1190–1190, 2018.
D A Butterfield and B Halliwell. Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease. Nat. Rev. Neurosci,20(3):148–160, 2019.
B Uttara, A V Singh, P Zamboni, and R T Mahajan. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. CurrNeuropharmacol, 7(1):65–74, 2009.
M S García-Ayllón, D H Small, J Avila, and J Sáez-Valero. Revisiting the role of acetylcholinesterase in Alzheimer’s disease: Cross-talk with P-tau and β-amyloid. Front. Mol. Neurosci.4:22–22, 2011.
C A Lane, M Kivipelto, and J Tuomilehto. Preventing cognitive decline. Lancet Neurol., 18(11):1036–1045, 2019.
M T Heneka. Neuroinflammation in Alzheimer’s disease. Lancet Neurol., 14(4):388–405, 2015.
M L Bolognesi. Multi-target-directed ligands discovery: Balancing anti-amyloid and anticholinesterase capacity in a single chemical entity. J. Med. Chem.62(8):3784–3802, 2019.
P Taylor. Acetylcholinesterase and Butyrylcholinesterase: Functional Roles in Brain and Nervous System Diseases. Pharmacol. Rev.70(1):10–33, 2018.
R Singh, S Sharma, and A Kumar. Neuroprotective role of saponins from medicinal plants. J. Med. Plant Res., 14(3):47–54, 2020.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
